CDNA stock forecast, quote, news & analysis
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers... Show more
Why CareDx (CDNA) Stock Is Up +29.6% in the Last 30 Days
Key Takeaways
- CareDx (CDNA) shares have climbed roughly 29.6% over the trailing 30 days, from about $53.83 to approximately $69.74.
- The move was propelled by a raised analyst price target from BTIG and renewed confidence following the positive resolution of a Medicare transplant coverage determination.
- Strong transplant testing demand, an expanded oncology pipeline, and raised full-year guidance have underpinned sustained investor enthusiasm.
- The stock has also risen sharply over the trailing three months, reflecting a broader re-rating of the precision diagnostics business.
CareDx (CDNA) Company Overview and Market Position
CareDx, Inc., branded as "The Transplant Company," is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. Its portfolio includes non-invasive molecular monitoring tests such as AlloMap Heart, AlloSure Kidney, AlloSure Heart, and AlloSure Lung, alongside integrated digital health and patient-support solutions that span the care journey before and after transplantation.
The company is a leading provider of genomics-based information for transplant patients, with workflows embedded across a large share of U.S. transplant centers. Investors follow CDNA closely because its testing business generates recurring, reimbursed revenue tied to longitudinal patient monitoring, while newer initiatives — including the AlloHeme cell therapy test and the acquisition of oncology diagnostics provider Naveris — extend its model into adjacent high-value markets.
CareDx (CDNA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CareDx shares have advanced from a closing level of roughly $53.83 to approximately $69.74, a gain of about 29.6%. The advance accelerated in late September, when the stock jumped roughly 13% in a single session following a bullish analyst action, before consolidating and pushing to new recent highs into mid-October.
The quarterly picture is even stronger. Over the trailing three months, shares have risen from roughly $38 in mid-July to current levels, a gain of about 82%. This multi-month surge reflects a sustained re-rating driven by better-than-expected earnings, raised guidance, and progress on the company's strategic transformation, rather than a single isolated catalyst.
What Drove CDNA Stock Price in the Last 30 Days
Several verified developments shaped the recent 30-day move. In late September, BTIG raised its price target on CareDx to $74 from $60 while reiterating a Buy rating, citing management's confidence after the positive resolution of a Medicare transplant local coverage determination (LCD), strong growth in the core transplant testing business, and the oncology pipeline including the Naveris acquisition. The announcement drove a double-digit single-day gain.
The favorable LCD outcome removed a meaningful reimbursement overhang that had weighed on sentiment earlier in the year. With clearer coverage visibility for surveillance testing across kidney, heart, and lung transplants, investors gained confidence in the durability of the company's core revenue stream. Additionally, anticipation has built ahead of CareDx's third-quarter 2026 results, which the company scheduled to report in late October.
Broader market rotation toward precision diagnostics and names with accelerating, reimbursed revenue growth has also contributed to positive sentiment, though company-specific fundamentals remain the dominant driver of the move.
What Drove CDNA Stock Performance Over the Last Quarter
The stock's larger quarterly advance reflects a series of fundamental milestones. In its second-quarter 2026 report, CareDx posted revenue of $132 million, up 52% year over year, while adjusted net income more than tripled to $20 million, or $0.37 per share. The company simultaneously raised its full-year 2026 revenue guidance to $490 million to $500 million and lifted its adjusted EBITDA outlook to $66 million to $78 million.
Earlier in the quarter, the Centers for Medicare & Medicaid Services affirmed coverage for CareDx's transplant surveillance testing, strengthening the reimbursement foundation. Strategically, the company completed its acquisition of Naveris, an oncology diagnostics provider focused on tumor-naive minimal residual disease (MRD) testing for viral-mediated cancers, and announced the divestiture of its Lab Products business for $170 million in upfront cash. These portfolio actions streamline the business around higher-growth testing and digital solutions while funding expansion into specialty oncology.
Trending AI Robots
For traders and investors seeking a systematic edge, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. These bots vary in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term swing trading to longer-horizon models. The selection is designed to help market participants quickly identify strategies that are currently resonating with market conditions. Reviewing the featured robots can provide a useful, data-driven complement to fundamental research.
CDNA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst is CareDx's third-quarter 2026 earnings report, scheduled for late October, along with any updates to full-year guidance. Investors will also monitor the integration of Naveris and the trajectory of its MRD testing volumes, as well as progress on pipeline programs such as AlloHeme and AlloSure Liver. Reimbursement policy remains a key sensitivity, given the sector's dependence on Medicare coverage determinations. Competitive dynamics in transplant and oncology diagnostics — including against players such as Natera (NTRA) — and broader healthcare spending trends are additional factors to watch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for CDNA shows an upward move is likely
CDNA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 207 similar instances where the Aroon Indicator showed a similar pattern. In 185 of the 207 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CDNA as a result. In 82 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in 238 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for CDNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for CDNA turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 37 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
CDNA broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.599) is normal, around the industry mean (64.450). P/E Ratio (32.750) is within average values for comparable stocks, (2.086). CDNA's Projected Growth (PEG Ratio) (48.410) is very high in comparison to the industry average of (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.146) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a molecular diagnostics company which develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients
Industry MedicalSpecialties